As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International
As part of the CROS NT Group global growth strategy, CROS NT Ltd today announced the acquisition of MDSL International - a specialist clinical Contract Research Organization (CRO) providing biometrics services such as Clinical Data Management and Statistical services. The financial details of the transaction remain confidential.
CROS NT Ltd, the UK branch of CROS NT, sees the acquisition as an important part of the overall group strategy. The deal adds additional resources to the existing group in the UK and will provide a new headquarters for the UK company in Maidenhead, close to London. MDSL International has built a reputation for providing strong consultancy and project work coupled with excellent customer service.
Andrew MacGarvey, CEO and President of CROS NT, said, "I am delighted to expand the UK operation through this acquisition. We are adding a highly experienced team to the business and further diversifying our customer base - both important objectives of the CROS NT Group. We will move our UK Headquarters to Maidenhead, giving us a great location in terms of on-going recruitment and access to our customers given its proximity to London. Coming shortly after our acquisition of Stat-Tech Services in the USA, this deal demonstrates our commitment to place expertise close to our customers and to grow to meet the increasing demand for our services."
Edmund Otun, the founder of MDSL International, said, "I am pleased to have concluded the deal with CROS NT. Being part of a larger entity allows us to provide additional resources to our existing clients - something they have been asking for. CROS NT has a very strong management team, with great experience in the CRO business. I will remain with the company providing consultancy for emerging companies seeking advice on getting their products to market or securing licencing deals."
Jo Marshall, MDSL International Managing Director, who will become the UK Country Manager for CROS NT Ltd added, "I am excited by this opportunity and looking forward to working with the CROS NT team. In addition to giving us greater critical mass here in the UK, this deal will give our existing customers access to the CROS NT technology portfolio which includes several Electronic Data Capture (EDC) platforms, a Clinical Trial Management System (CTMS), and electronic Patient Recorded Outcomes (ePRO) solutions."
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.